318 related articles for article (PubMed ID: 14655260)
1. Will the use of insulin analogs improve glycemic control during adolescence?
Dunger DB
Pediatr Diabetes; 2003 Jun; 4(2):61-3. PubMed ID: 14655260
[No Abstract] [Full Text] [Related]
2. [Long acting insulin analogs: possibly more stable glucose regulation].
Huvers F
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1674-8. PubMed ID: 15453119
[TBL] [Abstract][Full Text] [Related]
3. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes.
Hathout EH; Fujishige L; Geach J; Ischandar M; Maruo S; Mace JW
Diabetes Technol Ther; 2003; 5(5):801-6. PubMed ID: 14633345
[TBL] [Abstract][Full Text] [Related]
4. Prospective audit of the introduction of insulin glargine (lantus) into clinical practice in type 1 diabetic patients.
Gallen IW; Carter C
Diabetes Care; 2003 Dec; 26(12):3352-3. PubMed ID: 14633830
[No Abstract] [Full Text] [Related]
5. Studies show Lantus to be effective, safe and flexible in the treatment of type 1 diabetes.
Walczak IM
Diabetes Technol Ther; 2002; 4(5):744-5. PubMed ID: 12458569
[No Abstract] [Full Text] [Related]
6. [Advantages of fast-acting insulin analogs: preprandial greater HbA1c lowering -- postprandial lower weight].
MMW Fortschr Med; 2005 Aug; 147(33-34):45. PubMed ID: 16138637
[No Abstract] [Full Text] [Related]
7. Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes.
Deiss D; Kordonouri O; Hartmann R; Hopfenmüller W; Lüpke K; Danne T
Pediatr Diabetes; 2007 Jun; 8(3):157-62. PubMed ID: 17550426
[TBL] [Abstract][Full Text] [Related]
8. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
[TBL] [Abstract][Full Text] [Related]
9. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment.
Lepore G; Dodesini AR; Nosari I; Trevisan R
Diabetes Care; 2003 Apr; 26(4):1321-2. PubMed ID: 12663625
[No Abstract] [Full Text] [Related]
10. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
Fulcher GR; Gilbert RE; Yue DK
Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
[TBL] [Abstract][Full Text] [Related]
11. Effects of mixing glargine and short-acting insulin analogs on glucose control.
Kaplan W; Rodriguez LM; Smith OE; Haymond MW; Heptulla RA
Diabetes Care; 2004 Nov; 27(11):2739-40. PubMed ID: 15505016
[No Abstract] [Full Text] [Related]
12. Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program.
Philis-Tsimikas A; Zhang Q; Walker C
Am J Ther; 2006; 13(6):466-72. PubMed ID: 17122525
[TBL] [Abstract][Full Text] [Related]
13. Fasting and insulin glargine in individuals with type 1 diabetes.
Mucha GT; Merkel S; Thomas W; Bantle JP
Diabetes Care; 2004 May; 27(5):1209-10. PubMed ID: 15111549
[No Abstract] [Full Text] [Related]
14. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy.
Albright ES; Desmond R; Bell DS
Diabetes Care; 2004 Feb; 27(2):632-3. PubMed ID: 14747268
[No Abstract] [Full Text] [Related]
15. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
[TBL] [Abstract][Full Text] [Related]
16. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes.
Garg SK; Paul JM; Karsten JI; Menditto L; Gottlieb PA
Diabetes Technol Ther; 2004 Oct; 6(5):589-95. PubMed ID: 15628812
[TBL] [Abstract][Full Text] [Related]
17. Optimizing glycemic control with insulin glargine.
Williams JB
Diabetes Technol Ther; 2003; 5(3):471-3. PubMed ID: 12828834
[No Abstract] [Full Text] [Related]
18. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
19. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.
Kurtoglu S; Atabek ME; Dizdarer C; Pirgon O; Isguven P; Emek S;
Pediatr Diabetes; 2009 Sep; 10(6):401-7. PubMed ID: 19220776
[TBL] [Abstract][Full Text] [Related]
20. The insulin analog glargine during an unplanned pregnancy.
Cechurová D; Lacigová S; Jankovec Z; Haladová I; Zourek M; Krcma M; Rusavý Z; Turek J
Wien Klin Wochenschr; 2006 Oct; 118(19-20):619-20. PubMed ID: 17136338
[No Abstract] [Full Text] [Related]
[Next] [New Search]
